Introduction:
Last Updated 23 December 2009 Parkinson’s disease (PD) is one of the most common
neurodegenerative diseases in the elderly. Since we last reported on this
indication, we have expanded the scope of our report to reflect the increasing
physician awareness of nonmotor symptoms of PD, such as psychosis, dementia,
and depression. Therapies that can treat such symptoms represent areas of
commercial opportunity in PD drug development.
Questions Answered in This Report:
*
Once-daily formulations of dopamine agonists are competing in a
market traditionally dominated by immediate-release (IR) formulations.
How
will the new formulations affect the use of traditional dopamine agonists? How
will novel once-daily formulations of dopamine agonists fare in the face of
generic competition from IR formulations? Will this dynamic change between
markets? Which dopamine agonist will become the market leader?
*
Leading PD drugs will face generic competition during the
2008-2018 study period.
How will genericization affect the overall market?
How will it affect physician prescribing behaviors in the different markets?
*
The results of recent key clinical trials will affect treatment
algorithms in early PD. Among these are the results of the ADAGIO study, which
suggest a disease-modifying effect for the MAO-B inhibitor rasagiline (Teva
Pharmaceuticals/Lundbeck).
How will uptake of MAO-B inhibitors change over
the forecast? Do neurologists view this class as neuroprotective?
*
Results from the FIRST-PD and STRIDE-PD of Stalevo
(Novartis/Orion Pharma) suggest that the therapy is associated with both
positive and negative outcomes when used in early PD.
Do neurologists view
Stalevo as an effective treatment for early PD? How will trial data on Stalevo
affect the drug’s patient share?
*
The most significant unmet needs in PD remain neuroprotective/neurorestorative
therapies and therapies that target nonmotor symptoms.
What are thought
leaders’ opinions on the prospect of a true neuroprotective/neurorestorative
therapy? Will the treatment of nonmotor symptoms change over the forecast period?Scope:
Markets covered: United States, France, Germany, Italy,
Spain, United Kingdom, Japan.
Primary research: 40 country-specific interviews with
movement disorder specialists and neurologists.
Epidemiology: Prevalence of PD by country and age-group
(< 65 years and ≥ 65 years). Percentage of PD patients affected by
dementia.
Emerging therapies: Phase II: 18 drugs; Phase III/PR: 9
drugs; coverage of 28 select preclinical and Phase I products.
Market forecast features: Using market research, primary
research with key opinion leaders, and our proprietary forecasting model, we
forecast population sizes and sales of PD therapies through 2018.
Alternative market scenario: Juvantia Pharma/Santhera Pharmaceuticals’ alpha 2A adrenergic receptor antagonist fipamezole is approved as levodopa-adjunct therapy for PD in the United States and Europe.
Acadia/Biovail’s 5-HT2A receptor inverse agonist pimavanserin is approved for PD psychosis in the United States and Europe.